NPS Pharmaceuticals Inc. is the latest biotech to set a six-figure annual cost for an Orphan drug. While the company believes its Gattex teduglutide could reduce the overall cost of treating short bowel syndrome, the math may prove to add up for only a subset of cases.

Nevertheless, NPS says payers are ready to reimburse and does not expect patients to bear the brunt.